3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
8
Leukemia
3
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
blinatumomab
15
Cyclophosphamide
15
Cytarabine
14
Azacitidine
11
venetoclax
10
fludarabine
10
fludarabine phosphate
7
Methotrexate
7
Daunorubicin
7
Rituximab
6
Vincristine
5
Mercaptopurine
5
Whole-Body Irradiation
4
Melphalan
4
Idarubicin
4
Etoposide
4
Imatinib Mesylate
3
Granulocyte Colony-Stimulating Factor
3
Doxorubicin
3
Dexamethasone
3
Cladribine
3
Busulfan
3
Asparaginase
3
thymoglobulin
2
pembrolizumab
2
pegaspargase
2
nilotinib
2
midostaurin
2
daratumumab
2
Vindesine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
Anthracyclines
×
Other hematologic neoplasm
×
Clear all
NCT03760445
2020-01-09
HDM201 Added to CT in R/R or Newly Diagnosed AML
Novartis
Phase 1/2
Withdrawn